Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
Perfuze develops technology to treat acute ischemic stroke. The company was founded in 2018 and is based in Galway, Ireland.
Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.
Developer of a medical system designed to advance smoke evacuation and insufflation technologies for laparoscopic, endoluminal, endoscopic, colorectal, and robotic surgery. The company's system maintains a smooth surgical workflow that seamlessly integrates with existing systems and products and protects the operating room staff from potential hazards of surgical smoke and aerosolized viruses, enabling hospitals to develop an optimal solution for smoke evacuation and insufflation.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Shorla Pharma Limited is an Irish specialty pharmaceutical company that focuses on developing and manufacturing oncology drugs specifically targeting orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company offers products such as SH-111, a sterile injectable solution for treating T-cell leukemia in both pediatric and adult patients, and SH-105, another oncology drug. Shorla Pharma is committed to providing accessible and affordable life-saving treatments, contributing significantly to patient care and making a meaningful clinical impact in the field of oncology.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment. Established in 2015, the company aims to create novel therapeutics by targeting pathways involved in RNA modification. Originally known as Iceni Therapeutics Limited, it rebranded to Storm Therapeutics in June 2016. Through its innovative approach, Storm Therapeutics seeks to advance cancer therapeutics by leveraging the role of RNA in cellular processes.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
PQ Bypass, Inc. develops and manufactures medical devices to treat peripheral vascular disease through the minimally-invasive percutaneous surgical bypass. It offers products, such as DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System for the treatment of long-segment femoropopliteal disease. PQ Bypass, Inc. was incorporated in 2009 and is based in Milpitas, California.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.
Apica Cardiovascular is a pre revenue medical device company commercializing a technology for access and closure of the heart’s apex and the peripheral vascular system. The underlying technology has applications in a number of medical procedures such as Transcatheter Heart Valves (TAVI), AAA, and LVAD implantation. The technology standardizes access and closure for large bore therapeutic devices without loss of blood via minimally invasive surgical or percutaneous access on the beating heart. The technology has progressed to the point where it has proven the initial concept in animal and cadaver models and is now moving toward initial clinical trials.
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.
NOvate Medical Technologies is a New Orleans-based medical device development company, focused on commercializing high-quality, low-cost, and sustainable medical products while addressing critical global health needs. NOvate’s first product offering, InfaClip, previously known as SafeSnip, is a patented disposable plastic obstetric device that simultaneously cuts, clamps, and shields the infant, mother, and birthing attendant from infection, aimed at reducing maternal and neonatal mortality in developing countries.
Provesica is a Cambridge-based biopharmaceutical company specialising in overactive bladder. The Company’s development compound, XEN-D0501, is highly potent antagonist of the vanilloid receptor, TRPV1, and is about to start Phase 2 clinical development. In addition to XEN-D0501, Provesica owns a portfolio of intellectual property covering diverse TRPV1 antagonists suitable for development in overactive bladder or other indications where TRPV1 has been validated as an intervention target. Provesica was established in 2010 following the demerger of the overactive bladder and TRPV1 interests of Xention Ltd, an ion channel specialist drug discovery and development company. Provesica has so far raised £4 million in finance to progress its lead programme through Phase 2 development.
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
TriMed Research, Inc. engages in the research and development of therapeutic products primarily related to mammary gland protein designated as MAA.
Diabetica Ltd was established in September 2004 to commercialise discoveries at the Diabetes Research Group in the University of Ulster, under the leadership of scientific co-founders Prof Peter Flatt, Dr Neville McClenaghan and Prof Finbarr O'Harte.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.